WORLD CLASS QUALITY.

SYNTHIMED CAPABILITIES

 

WORLD CLASS QUALITY IN

DESIGN, EQUIPMENT, OPERATION

DELIVERS PRODUCTS OF

WORLD-QUALITY STANDARDS

LARGEST CUMULATIVE

REACTOR CAPACITIES

AUDITED BY REGULATORY AUTHORITIES

USFDA, KFDA, PMDA, ANVISA, EDQM

22

MANUFACTURING BLOCKS

MANUFACTURING

Synthimed Labs’ Advanced Manufacturing Facilities

Multi-Locational Manufacturing Sites

 

Largest Cumulative Reactor Capacities

  • Synthimed Labs possesses one of the largest cumulative reactor capacities in North India, enabling complex reaction capabilities and stringent controls to form the ideal base for innovative and quality products.

Focus on Operational Excellence and Quality Circles

  • The capacity build-up is rooted in the company’s focus on operational excellence and quality circles, aiming to continuously improve processes, eliminate inefficiencies, and facilitate lean procedures.

Rigorous Regulatory Inspections and Audits

  • The flagship manufacturing site at Derabassi is periodically inspected and audited by regulatory authorities like USFDA, KFDA, PMDA, ANVISA, EDQM, among others, ensuring adherence to global quality standards

World-Class Quality Assurance

  • Both manufacturing facilities in North India have been designed to ensure world-class quality in design, equipment, and operations, operating in full compliance with Current Good Manufacturing Practice (cGMP) regulations.

Stringent Compliance with cGMP Regulations

  • The API Jammu, India facility fully complies with cGMP requirements, underscoring the company’s commitment to stringent quality standards.

International Regulatory Oversight

  • The Derabassi manufacturing facility is regularly inspected by local and international health authorities, such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), among others, further validating its commitment to global quality standards.

Synthimed Labs Pvt. Ltd. has multi-locational manufacturing sites for producing APIs. The cGMP manufacturing facility at Punjab with 22 manufacturing blocks comprises of a Pilot Plant, dedicated blocks and multi-purpose blocks designed to comply with stringent USFDA and other regulatory standards of approval.

An API manufacturing facility in the state of Jammu & Kashmir complying with cGMP requirements is adding to the capacities of the organization.

The company possesses one of the largest cumulative reactor capacities in North India. Complex reaction capabilities and stringent controls provide an ideal base for innovative and quality products.

DERABASSI FACILITY

 

  • Twenty two dedicated and multipurpose cGMP manufacturing plants.
  • Pilot plant facility.
  • Dedicated facility for Oncology Products with world class Isolators.
  • Dedicated Oral Solid Dosage facility for largest product Clarithromycin Granules.
  • Four Solvent Recovery Plant.

JAMMU FACILITY

  • Three Dedicated and multipurpose cGMP manufacturing plants.

MANUFACTURING CAPABILITIES

DERABASSI FACILITY

  • Installed Reaction Capacity of 505 KL with 185 Stainless Steel reactors and 50 Glass lined reactors, facility is equipped with cryogenic reactor
  • 200 MT production capacity every month for Intermediate and APIs
  • 2000 KL solvent distillation capacity every month
  • High Pressure hydrogenation facility up to 20 kg/cm2
  • GMP pilot plant suitable for advance intermediate, Key starting Material and for API
  • Purified water system to meet USP39 Quality
  • ZERO discharge facility

JAMMU FACILITY

  • Installed Reaction Capacity of 162 KL
  • 30 MT API Production capacity every month

REACTION CAPABILITIES

Cyclization
Grignard
Hydrolysis
Methylation
Hydrogenation
Condensation
Decarboxylation
Reduction
Oxidation
Racemization
Hydrolysis
Weinreb

WAREHOUSING

Facility is equipped with the storage capacity of 1200 KL liquid and 350 MT solid with controlled temperature storage.

SUPPLY CHAIN

Our effective supply chain systems ensure ON TIME IN FULL delivery to commitments made with customers spread across the globe. Synthimed Labs operates abiding to the principles of business continuity and has taken suitable measures to mitigate and dependency on incoming supplies.

Quality Assurance Systems

At Synthimed Labs, our commitment to quality is unwavering. We prioritize adherence to stringent QA policies to ensure that our operations consistently uphold the highest standards of quality and compliance, aligning with globally recognized best practices.

Mainstay of Competitiveness

  • Emphasis on Quality: Quality serves as the cornerstone of our competitiveness, driving our pursuit of excellence in all aspects of our operations.

 

Integration of Quality Assurance

  • Interface Between R&D and Manufacturing: While Quality Assurance functions independently, it functions as a crucial interface between our Research and Development and manufacturing divisions. It strictly adheres to standardized quality systems, ensuring consistency, effectiveness, and efficiency across all our API manufacturing activities at various locations.

Organizational Engagement for Quality

  • Shared Responsibility: Every facet of our organization is dedicated to championing the quality ethos, ensuring the implementation of global cGMP standards at every level and during every process.

Effective Quality Systems & Policies

  • Continuous Improvement: Our systems and policies are designed to drive effectiveness through regular quality reviews, audits, and compliance assessments to uphold regulatory standards and customer expectations.

Focus on Improvement and Prevention

  • Proactive Approach: We focus on reviewing failures, rejections, market complaints, deviations, non-compliances, product stability, and planning corrective and preventive actions to continually enhance our processes.

Striving for Excellence

  • Constant Pursuit of Quality Excellence: Our relentless endeavor is to consistently achieve “QUALITY EXCELLENCE,” reflecting our ongoing commitment to unparalleled quality standards.

ESTABLISH QUALITY STANDARDS

TRAIN PERSONNEL

DEVELOP PROCESSES TO ACHIEVE SET STANDARDS

CLOSE MONITORING

CONSISTENCY AT EVERY STAGE

GLOBAL REGULATORY APPROVALS

Sr. No
Date of Audit
Regulatory Agencies
1
August 2021
ISO 9001: 2015 site audit
2
February 2021
ISO 14001:2015 site audit
3
February 2021
ISO 45001:2018 site audit
4
March 2020
15 USDMF File products
5
February 2020
COPP for Acamprosate Calcium, Anastrozole, Aripiprazole, Atorvastatin Calcium, Cinacalcet Hydrochloride, Camylofin Dihydrochloride, Clarithromycin, Clarithromycin Citrate, Clarithromycin Granules, Clopidogrel Hydrochloride, Clopidogrel Bisulphate, Donepezil Hydrochloride, Ezetimibe, Fexofenadine Hydrochloride, Imatinib Mesylate, Ivabradine Hydrochloride, Ivabradine Oxalate, Letrozole, Mecloxamine Citrate, Nateglinide, Naratriptan Hydrochloride, Pioglitazone Hydrochloride, Quetiapine Fumarate, Risedronate Sodium, Rosuvastatin Calcium, Ropinirole Hydrochloride, Ranolazine, Temozolomide, Valganciclovir Hydrochloride.
6
February 2019
Written confirmation for active substance into European Union in accordance with Article 46b(2)(b) of ‘Directive 2001/83/EC by National Authority (CDSCO) India for Acamprosate Calcium, Anastrozole, Aripiprazole, Atorvastatin Calcium, Cinacalcet Hydrochloride, Clarithromycin, Clarithromycin Citrate, Clarithromycin Granules (27.5%, 33%, 42%), Clopidogrel Hydrochloride, Clopidogrel Bisulfate, Donepezil Hydrochloride, Ezetimibe, Fexofenadine Hydrochloride, Imatinib Mesylate, Letrozole, Nateglinide, Pioglitazone Hydrochloride, Quetiapine Fumarate, Risedronate Sodium 2.5 Hydrate, Temozolomide, Naratriptan Hydrochloride, Ropinirole Hydrochloride, Ivarbadine Hydrochloride, Valganciclovir Hydrochloride, Ivabradine Oxalate, Lisdexamfetamine Dimesylate, Mecloxamine Citrate.
7
November 2018
Agency for Medicinal Products and Medical devices of the Republic of Slovenia for Clopidogrel Hydrochloride, Imatinib Mesylate and Clarithromycin, Clarithromycin Granules
8
July & August 2018
ISO 9001: 2015 site audit
9
March 2018
16 USDMF file products
10
March 2018
COPP for Acamprosate Calcium, Anastrozole, Aripiprazole, Atorvastatin Calcium, Cinacalcet Hydrochloride, Clarithromycin, Clarithromycin Citrate, Clarithromycin Granules, Clopidogrel Hydrochloride, Clopidogrel Bisulphate, Colesevelam Hydrochloride, Donepezil Hydrochloride, Dutasteride, Dapoxetine Hydrochloride, Ezetimibe, Fexofenadine Hydrochloride, Ivabradine Hydrochloride, Letrozole, Mecloxamine Citrate, Nateglinide, Naratriptan Hydrochloride, Pioglitazone Hydrochloride, Quetiapine Fumarate, Risedronate Sodium, Rosuvastatin Calcium, Ropinirole Hydrochloride, Ranolazine, Sevelamer Carbonate, Temozolomide, Telmisartan, Ivabradine Oxalate, Valganciclovir Hydrochloride.
Year
Country Authorities
Products
2018
United State Food & Drug Administration (USFDA), US
For All Marketed APIs
2017
United State Food & Drug Administration (USFDA), US
For All Marketed APIs
2017
Pharmaceutical and Medical Devices Agency (PMDA), Japan
Trityl Olmesartan Medoxomil (Intermediate)
2016
EDQM, France +ANSM, France
Clarithromycin (EDQM), Clopidogrel Hydrochloride (ANSM, France)
2015
United State Food & Drug Administration (USFDA), US
Acamprosate Calcium, Aripiprazole, Clarithromycin Extrapure, Donepezil Hydrochloride, Nateglinide, Risedronate Sodium, Temozolomide
2015
NOM, Greece
Clarithromycin Coated Granules
2014
Cofepris, Mexico
Dutasteride, Quetiapine Fumarate, Atorvastatin Calcium, Aripiprazole, Clopidogrel Bisulphate, Fexofenadine Hydrochloride, Risedronate Sodium
2014
Anvisa, Brazil
Clarithromycin
2011
United State Food & Drug Administration (USFDA), US
Clarithromycin, Donepezil Hydrochloride, Acamprosate Calcium, Ropinirole Hydrochloride, Naratriptan Hydrochloride
2011
German Health Authority, Behorde fur Gesundheit und Verbraucherschutz, Germany
Atorvastatin Calcium, Aripiprazole
Year
Country Authorities
Products
2011
National Organization of Medicine (NOM), Greece
Clarithromycin, Clarithromycin Coated Granules
2011
Therapeutic Goods Administration (TGA), Australia
Clarithromycin, Donepezil Hydrochloride, Letrozole, Ropinirole Hydrochloride, Acamprosate Calcium, Aripiprazole, Pioglitazone Hydrochloride, Atorvastatin Calcium
2010
Pharmaceutical and Medical Devices Agency (PMDA), Japan
Risedronate Sodium, Pioglitazone Hydrochloride
2010
Korean Food & Drug Administration (KFDA), Korea
Risedronate Sodium, Ezetimibe
2008
German Health Authority, Behorde fur Soziales, Familie, Gesundheit und Verbraucherschutz, Germany
Atorvastatin Calcium, Clopidogrel Besylate, Aripiprazole
2007
National Institute of Pharmacy (NIP), Hungary
Anastrozole
2007
United State Food & Drug Administration (USFDA), US
Clarithromycin
2006
Therapeutic Goods Administration (TGA), Australia
Clarithromycin
2004
Ministry of Health, Iran
Clarithromycin, Atorvastatin Calcium, Clarithromycin Granules

Our regulatory process also covers:

  • Submission of product registration applications in the form of CTD-Dossiers, marketing applications, ANDA, NDA etc.
  • Response to queries or deficiencies from regulatory bodies / customers.
  • Inspections and inspection reports.
  • Post approval / marketing surveillance by regulatory bodies.
  • Submission of annual updates to regulatory bodies.

EHS MANAGEMENT SYSTEM

ENVIRONMENT, HEALTH & SAFETY

As an integral part of our EHS philosophy, we think & work together responsibly so that employees & community at large and the environment including natural resources are protected and maintained leaving minimal environmental footprints. Over the record on EHS excellence, Synthimed Labs has adopted a top down approach and embraced the principles and code of best EHS practices into the EHS management system.

Emergency Planning & Fire Protection System

Synthimed Labs has an Onsite Emergency Plan considering all emergency situations. Synthimed Labs have installed all kinds of fire protection systems to meet any kind of emergency.

Fire Hydrant System:

  • Facility is safeguard with sufficient hydrant water storage, and related hydrant points across the plants.

Portable Fire Extinguishers: 

  • Facility is safeguard with sufficient and all kind of fire extinguishers across the plants.

 Fire Alarm System:

  • Facility is safeguard with satisfactory instrumentation system to handle emergency at site. Sufficient manual call points and emergency sirens are available at site.

SIX MONTH COMPLIANCE REPORT

SLPL DB SIX MONTH COMPLIANCE REPORT (June 2024)

SLPL SAMBA JAMMU SIX MONTH COMPLIANCE REPORT (June 2024)

SLPL FOCAL POINT SIX MONTH COMPLIANCE REPORT (June 2024)

WASTE MANAGEMENT

Synthimed Labs (Derabassi)

 

Synthimed Labs Pvt. Ltd., Derabassi  is engaged in manufacturing Bulk Drugs (Active Pharmaceutical Ingredients) like Clarithromycin, Azithromycine, Letrozole, Anastrazole, Fexofenadine HCl, Fax-10, Atorvastatin Calcium, Clopidogrel Bisulphate, Acamprosate Calcium, Ropinarole, Pioglitazone Hydrochloride, Clarithromycin Granules etc. with green technology at Village Bhagwanpur, Derabassi, Distt. Mohali – Punjab.

As a socially responsible company, Synthimed Labs – Derabassi is continuing its efforts with commitment to consistently minimize the impact on environment.

We comply with all local & national legislation pertaining to safety, health & environment.

At Synthimed Labs three types of pollutants are being generated  (liquid, solid & gaseous). These pollutants are effectively treated to give zero discharge facility.

This facility has the capacity to treat effluent 240 KL low TDS in ETP and 165 KL high TDS with New MEE and 65 KL high TDS with OLD MEE.

Liquid waste is treated in ETP & Multi Effect evaporator

  • Incinerable Solid waste at Incinerator and non Incinerable being dispose at CTSDF  facility at Nimbua, Punjab
  •  Gaseous in Air Pollution Control Devices Like Alkali Wet scrubbers.

Synthimed Labs (Jammu)

 

Synthimed Labs Pvt. Ltd., Jammu is engaged in manufacturing Bulk Drugs (Active Pharmaceutical Ingredients) like, Atorvastatin Calcium, Clopidogrel Hydrogen, Nitazoxanide, etc. with green technology at Industrial Growth Center, Phase-I, Samba, Jammu & Kashmir.

As a socially responsible company, Synthimed Labs – Jammu is continuing its efforts with a commitment to consistently minimize the impact on the environment.

We comply with all local & national legislation pertaining to safety, health & environment.

At Synthimed Labs, Jammu three types of pollutants are being generated (liquid, solid & gaseous). These pollutants are effectively treated and treated water is used for cooling tower and plantation. This facility has the capacity to treat effluent 86KL low TDS in ETP and 48 KL high TDS in MEE.

  • Liquid waste is treated in Effluent Treatment Plant & Multi Effect Evaporator.
  • Incinerable Solid waste at Incinerator and non Incinerable being stored in Hazardous Waste Room inside the premises.
  • Air Pollution Control Devices like Alkali Wet scrubbers are provided for Gaseous emissions and Multi Cyclone Dust Collector are provided for particulate matter.

CHEMISTRY

See below our partial list of

REACTION & REAGENT CAPABILITIES 

REACTION CAPABILTIES
REAGENT CAPABILTIES
Grignard
S-CBS Reagent
Chiral Reduction
S-CBS Reagent
Chemical Resolution
(+) CSA, L (+) Tartaric acid
Biotransformations
Enzyme mediated resolution using Hydrolases D
Organometallic
RMgX
Organoborane Chemistry
Boran, DMS
Palladium Chemistry (take from Sheikh)
Pd reagents, Phospho Ligands
Cyanation
NaCN
Chlorination
POCl3, HCl
Bromination
Bromine/ HBr in Acetic acid, NBS, DBH
Nitration
HNO3/ H2SO4
Reductive Amination
Hydrazine Hydrate, Pd/C
Catalytic Hydrogenation
H2, Raney Nickel, Pd/C
Reduction
NaBH4, LiAlH4, L-selectride
Condensation
Potassium amide
Cyclization
Acylating reagent/AlCl3
Friedel Crafts
AlCl3
Wittig
Methyltriphenylphosphonium Bromide
Mesylation/Tosylation
Methanesulfonyl Chloride- Tosyl Sulfonylchloride
Methylation
MeI/KOH, Dimethyl sulphate/KOH
Demethylation
N-Demethylation using Sodium acetate/I2
Dehydrogenation
DDQ, N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA) in Toluene
Gewald Reaction
EDCI / HOBT